Needham Reiterates Buy on NeoGenomics, Maintains $21 Price Target

NeoGenomics, Inc. -2.96%

NeoGenomics, Inc.

NEO

14.09

-2.96%

Needham analyst Mike Matson reiterates NeoGenomics (NASDAQ: NEO) with a Buy and maintains $21 price target.
Every question you ask will be answered
Scan the QR code to contact us
whatsapp
Also you can contact us via